Sort   by:  
 Page size 
UnknownEfficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
Not available
S-EPMC3675695 | biostudies-literature
UnknownOxidative stress and starvation in Dinoroseobacter shibae: the role of extrachromosomal elements.
Not available
S-EPMC4373377 | biostudies-literature
UnknownValidation of human microRNA target pathways enables evaluation of target prediction tools.
Not available
S-EPMC7797041 | biostudies-literature
Genomicsena-DATASET-TAU-03-04-2017-19:28:40:078-460 - samples
Targeted resequencing of samples was done with TruSeq custom amplicon low input kit (TSCA-LI, Illumina). The oligo capture probes were designed to include a prefix of 8 random nucleotides at the 5 end of each probe. The assay is designed such that each targeted locus is annealed with two probes, res...
EGAD00001003275 | EGA
Genomicsena-DATASET-TAU-08-04-2017-14:02:11:924-149 - samples
Description not provided
EGAD00001003280 | EGA
MetabolomicsATF6 activation alters colonic lipid metabolism causing tumor-associated microbial adaptation

The induction of endoplasmic reticulum unfolded protein responses (UPRER) contributes to cancer development and progression. We recently linked microbiota-related triggers to the tumor-promoting role of signal transducer activating transcription factor 6 (ATF6) in the colon. Here we substantiate ...

2025-07-02 | MTBLS7387 | MetaboLights
MetabolomicsTargeting PI3K inhibitor resistance in breast cancer with metabolic drugs

Activating PIK3CA mutations, present in up to 40% of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (Her2-) breast cancer (BC) patients, can be effectively targeted with the alpha isoform-specific PI3K inhibitor Alpelisib. This treatment significantly improves ...

2026-08-21 | MTBLS11671 | MetaboLights
GenomicsSuppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down Syndrome
Children with Down Syndrome (DS) are prone to development of high risk B-cell precursor ALL (DS-ALL) that differs genetically from most sporadic pediatric ALLs. Increased expression of CRLF2, the receptor to thymic stromal lymphopoietin (TSLP) characterizes about half of DS-ALLs and also a subgroup ...
EGAS00001002410 | EGA
GenomicsDAC for data acquired during the Down Syndrome acute lymphoblastic leukemia project. The project was performed with clinical samples of the AIEOP-BFM trial.
Data Access Committee EGAC00001000644
EGAC00001000644 | EGA
UnknownSurgical data science - from concepts toward clinical translation.
Not available
S-EPMC9135051 | biostudies-literature
Sort   by:  
 Page size